Howard Kelly Joins Oxyphen's Board of Directors
News Nov 13, 2006
Oxyphen AG has announced that Howard Kelly has joined the company's Board of Directors. Kelly will support Oxyphen's ongoing international expansion and efforts to reach a technology and manufacturing leadership position to serve OEM companies in areas of track-etched membrane applications.
Targeted sectors are in drug discovery, diagnostics, rapid microbiology, drug delivery and bioprocess.
Howard Kelly brings an impressive background of business expertise and industry knowledge to Oxyphen.
He has extensive international management experience that spans diverse departments such as manufacturing, sales, marketing, strategy, regulatory, R&D, and business development.
In the BioScience Division of Baxter, he led an expansion into Asia, Japan, and Latin America, improving both sales growth and profitability.
He also started Baxter's BioSurgery business in North America. Mr. Kelly's most recent experience was with Boston Scientific, where he was a vice president and project leader for Europe.
He also served as CEO of Whatman plc, a UK-based multinational where he led a restructuring of the company.
Mr. Kelly began his career as a Naval Aviator in the United States Navy and achieved the rank of Commander, serving in both the active and reserve forces.
Mr. Kelly's academic accomplishments include a BSc in bioengineering and an MBA in international management.
"Howard brings an incredible wealth of knowledge and wisdom to Oxyphen from having run a leading track-etched membrane company as the CEO. Howard is going to be a terrific Director and we're excited and honoured that he has chosen the Oxyphen board to serve on," said Chairman and CEO Annette Nieweg.
"Annette and her team have done an incredible job in developing a pure membrane research center into the world's highest quality track-etched membrane manufacturing and processing company with an incredible track record in the automotive industry," said Howard Kelly.
"I am especially looking forward in supporting this small but powerful newcomer in the life science field from a start-up to the leader in its industry."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.